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Abstract
Since Otto Warburg linked mitochondrial physiology and oncogenesis in the 1930s, a number of studies have focused on
the analysis of the genetic basis for the presence of aerobic glycolysis in cancer cells. However, little or no evidence exists
today to indicate that mtDNA mutations are directly responsible for the initiation of tumor onset. Based on a model of
gliomagenesis in the mouse, we aimed to explore whether or not mtDNA mutations are associated with the initiation of
tumor formation, maintenance and aggressiveness. We reproduced the different molecular events that lead from tumor
initiation to progression in the mouse glioma. In human gliomas, most of the genetic alterations that have been previously
identified result in the aberrant activation of different signaling pathways and deregulation of the cell cycle. Our data
indicates that mitochondrial dysfunction is associated with reactive oxygen species (ROS) generation, leading to increased
nuclear DNA (nDNA) mutagenesis, but maintaining the integrity of the mitochondrial genome. In addition, mutational
stability has been observed in entire mtDNA of human gliomas; this is in full agreement with the results obtained in the
cancer mouse model. We use this model as a paradigm of oncogenic transformation due to the fact that mutations
commonly found in gliomas appear to be the most common molecular alterations leading to tumor development in most
types of human cancer. Our results indicate that the mtDNA genome is kept by the cell as a ‘‘genetic sanctuary’’ during
tumor development in the mouse and humans. This is compatible with the hypothesis that the mtDNA molecule plays an
essential role in the control of the cellular adaptive survival response to tumor-induced oxidative stress. The integrity of
mtDNA seems to be a necessary element for responding to the increased ROS production associated with the oncogenic
process.
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Introduction
Mitochondria are central to cell metabolism, being the principal
energy source of the cell, thanks to the cytochrome enzymes of
terminal electron transport and the enzymes of the citric acid
cycle, fatty acid oxidation, and oxidative phosphorylation. This
energy is gradually converted into a proton gradient. Mitochon-
dria use this gradient to synthesize ATP, which is later employed
for biosynthetic reactions [1,2]. On the other hand, changes in
mitochondrial membrane permeability lead to the release of
proapoptotic mediators regulating a number of signaling cascades,
including apoptosis [3,4]. Therefore, mitochondria are central
organelles that control life and death of the cell.
It has been revealed that mitochondrial dysfunction is one of the
most common and consistent phenotypes of cancer cells [5]. A
number of notable differences in the mitochondria of normal and
cancer cells have been described. These include differences in
mitochondrial metabolic activity [6,7], the molecular composition
of the mitochondria and the mitochondrial DNA (mtDNA)
sequence [8,9], as well as alterations of nuclear genes that may
affect mitochondrial function [10–12].
Recent studies have suggested that alterations in mtDNA may
be associated with malignant progression, increasing the metastatic
potential of tumor cells, and that this phenomenon is mediated by
the overproduction of reactive oxygen species [13,14]. The term
‘‘reactive oxygen species’’ (ROS) encompasses a wide range of
molecules. The unpaired electrons of oxygen react to form
partially reduced highly reactive species that are classified as ROS,
including superoxide radical anions (O2
2) and hydrogen peroxide
(H2O2). Various enzyme systems produce ROS, although
mitochondrial oxygen metabolism is the dominant source of
ROS and results from the incomplete coupling of electrons and H
+
with oxygen in the electron transport chain.
Reactive oxygen species are emerging as critical signaling
molecules. Traditionally, ROS have been considered as a toxic
product of cellular metabolism, but it has become appreciated that
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transformation and cancer. Increased numbers of ROS can drive
a cycle of genomic instability leading to DNA double-strand
breaks (DSBs) and altered repair mechanisms that can result in the
acquisition of genomic changes. Increased intracellular levels of
ROS have also been reported to mediate some of the biological
effects of several oncogenic genes such as HRas
V12. Among these
biological effects, the most important ones are the onset of
premature senescence, the generation of genomic instability [15],
and malignant transformation [16]. Furthermore, high levels of
ROS have been detected in several human cancer cell lines as well
as in human tumors from different tissues.
However, it is not only increased levels of intracellular ROS that
affect nuclear DNA (nDNA), mtDNA is a particularly vulnerable
target because of its proximity to the electron transport chain
constituents. Reactive oxygen species mediated mutations in
mtDNA have recently emerged as an important variable in
carcinogenesis [17]. Moreover, it has been reported that
mitochondria play a critical role in replicative senescence and
oncogene-induced senescence (OIS), and several mitochondrial
changes, including an increase in the production of ROS, were
reported in cells with short telomeres [18,19]. On the other hand,
the results of mtDNA instability in tumorigenesis have been
questioned under the assumption that most of the apparent
findings constituted laboratory or documentation errors [20–22].
Taking these reports all together, the present study aims to
analyze whether or not there is a real relationship between
oxidative stress and mitochondrial alterations in the process of
tumorigenesis. In order to carry out these studies, we used a mouse
model of gliomagenesis in the hope of understanding the
mitochondrial phenotype contributions to the formation of tumors
from the beginning of the oncogenic process to high-grade tumors.
In addition to the mouse model, entire mtDNA genomes from 11
human glioma patients were sequenced in order to quantify and
characterize mtDNA instability.
Results
Oncogene-induced ROS generation is associated with
chromosomal instability
Previously, in a model of gliomagenesis, we described the
resistance of astrocytes to Ras-induced senescence in the presence
of high levels of ROS and DNA damage despite DNA damage
response (DDR) activation [23]. Moreover, in this context, the loss
of the Rb locus favors tumor progression and confers a selective
advantage to the tumor, increasing the astrocyte’s proliferative rate
and favoring the inactivation of stress pathways, thus increasing
cellular transformation.
To this purpose, conditional Rb mutant mouse astrocytes were
infected with a retrovirus-encoding mutant Ras allele (HRas
V12)
and the recombinase Cre that targets the loxP sequences flanking
exon 19 of the Rb gene [24]. Thus, we managed to mimic the
characteristic upregulation of signaling pathways by introducing a
constitutively activated isoform of Ras and cell cycle deregulation
by genetically inactivating the pocket protein Rb. In this context,
the loss of the Rb locus favors the progression of low-grade gliomas
to higher-grade tumors. The tumors derived from Ras
V122expres-
sing astrocytes bore a strong similarity to human low-grade
gliomas, whereas the ones obtained after combining Ras
V12
expression and Rb loss were similar to high-grade gliomas
(glioblastoma multiforme, GBM) [23]. Therefore, in order to
examine the role of mtDNA mutations in the development of
tumor cells, four groups of primary astrocytes (cRb
loxP/loxP,
Rb
loxP/loxP/Ras
V12, cRb
2/2 and cRb
2/2/Ras
V12) and two cell
lines derived from tumors formed by primary astrocytes Rb
loxP/
loxP/Ras
V12 and cRb
2/2/Ras
V12 in SCID mice (T653 and T731,
respectively) were chosen (Table 1).
In the first approach and in order to verify whether or not the
expression of oncogenic Ras induces higher levels of intracellular
ROS in astrocytes, we measured ROS levels in our primary
cultures and cell lines to determine whether or not they differed
between the experimental groups.
The HRas
V12-expressing astrocytes (Rb
loxP/loxP/Ras
V12 and
cRb
2/2/Ras
V12) showed noticeably higher levels of intracellular
ROS than cRb
loxP/loxP and cRb
2/2 (Figure 1). As mentioned
before, HRas
V12 has been reported to induce ROS accumulation
and this property was linked to the ability of oncogenic Ras to act
as a transforming gene [16,25]. Curiously, the ROS levels detected
in cell lines T653 and T731 were lower despite the expression of
oncogenic Ras (Figure 1).
Several reports have linked the expression of HRas
V12 with the
induction of DNA damage, chromosomal instability (CIN), and
aneuploidy [15,26,27]. Moreover, the chromosomal instability
caused by HRas
V12 could be rescued by treating the cells with
scavengers of reactive oxygen species [15,28,29]. These reports
suggest that HRas
V12 induces genomic instability, at least in part,
by increasing intracellular ROS levels [27,30].
Consistent with these data, we wanted to confirm whether or
not the expression of the activated oncogene HRas
V12 and
therefore the high levels of ROS were related to CIN in our
astrocytes. To assess the effects of HRas
V12 and Rb loss, we
analyzed the karyotype of the infected primary cultures and cell
lines. Both cRb
loxP/loxP and cRb
2/2 primary astrocytes main-
tained a normal diploid genome (Figure 2). However, a significant
proportion of astrocytes became aneuploid in the presence of
HRas
V12 (Rb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12), of which
around 30% of these astrocytes presented .80 chromosomes per
cell, double the number of chromosomes found in the control cells.
Moreover, there was no striking difference in the degree of
aneuploidy between Rb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12,
Table 1. Characterization of cell lines and primary astrocytes.
Groups Rb loss HRas
V12 Tumor Formation
Primary astrocytes (cRb
loxP/loxP) M1/M2 22 2
Primary astrocytes (cRb
loxP/loxP/Ras
V12) M3/M4 2 ++
Primary astrocytes (cRb
2/2) M5/M6 + 22
Primary astrocytes (cRb
2/2/Ras
V12) M7/M8 ++ +
T653 cell line M9 2 ++
T731 cell line M10 ++ +
doi:10.1371/journal.pone.0023327.t001
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chromosome-destabilizing effect of HRas
V12 was very rapid, and
primary astrocytes were harvested for karyotyping in no more than
a few cell cycles after infection (six days after infection). Although
HRas
V12 is able to induce numerical chromosomal instability by
massive aneuploidy, it also causes structural chromosome
abnormalities [23]. Hence, these numerical and structural
chromosome abnormalities show that activated Ras is sufficient
for inducing chromosomal instability in the absence of other
signals, suggesting that Ras-induced chromosomal instability arises
from ROS accumulation and DNA replication.
When we analyzed the karyotype of the cell lines T653 and
T731, we found that of the cells analyzed in both cell lines,
virtually 100% were aneuploid. Curiously, and in contrast to
primary astrocytes, in the cell lines most of the cells analyzed
showed a chromosome number greater than 60, and a large
percentage of these presented .80 chromosomes per cell. These
data suggest that in the process of tumorigenesis and in the
successive passes suffered by the cell lines, there was a selection
process that favored the cells with a higher number of
chromosomes.
Cytochrome c oxidase activity correlates with increased
ROS generation
Since the intracellular accumulation of ROS is linked to
increased mitochondrial activity, we analyzed the mitochondrial
activity in our experimental groups. Mitochondrial activity can be
measured by assaying for mitochondrial-specific enzymes. Specif-
ically, we analyzed the mitochondria-specific cytochrome c
oxidase activity in soluble and membrane-bound mitochondria
samples. The enzyme cytochrome c oxidase is a large transmem-
brane protein located in the inner membrane of mitochondria,
and it is the terminal electron acceptor in the electron transfer
chain.
When we determined cytochrome c oxidase activity in the
different groups of cells, we observed that Rb
loxP/loxP/Ras
V12 and
cRb
2/2/Ras
V12 astrocytes had a higher cytochrome c oxidase
activity than cRb
loxP/loxP, cRb
2/2, T653 and T731 cells. In
addition, this higher mitochondrial activity was correlated with the
enhanced levels of ROS observed in Rb
loxP/loxP/Ras
V12 and
cRb
2/2/Ras
V12 astrocytes (Figure 3).
Since the staining of astrocyte cells with DHE suggested that the
mitochondria were the source of this ROS, we used MitoTracker
Red CMXRos to study how oncogenic Ras affects the distribution
and quantity of mitochondria. In order to label the mitochondria,
the cells were simply incubated with MitoTrackerR probes, which
passively diffuse across the plasma membrane and accumulate in
active mitochondria, thus giving an estimate of the mitochondrial
mass and position in cells.
After labeling with MitoTracker Red CMXRos, we observed
red fluorescence all over the cytoplasm in cells expressing
oncogenic Ras, showing an increase of mitochondrial mass in
the primary astrocytes (Rb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12)
compared to the cell lines T653 and T731, in which the
fluorescence was less intense. On other hand, we observed a
dramatic increase in perinuclear mitochondrial mass in the control
Figure 1. Ras
V12 expression increases the levels of ROS. Primary astrocytes and cell lines were assayed for dihydroethidium (DHE)
fluorescence, indicative of ROS production, and visualized by fluorescent microscopy. Under identical imaging conditions, DHE oxidation was
increased in Rb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12 astrocytes.
doi:10.1371/journal.pone.0023327.g001
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loxP/
loxP) and astrocytes without Rb (cRb
2/2), but we did
not observe a decrease in the number of mitochondria per cell.
The distribution of mitochondria around the nucleus implies a
lower efficiency (Figure 4).
Analysis of mouse mtDNA genomes
Primary mouse astrocytes, cRb
loxP/loxP, cRb
2/2,R b
loxP/loxP/
Ras
V12 and cRb
2/2/Ras
V12, as well as the two cell lines T653 and
T731, were sequenced for their entire mtDNA genomes. In order
to avoid false positives and/or negatives and documentation errors
as much as possible [20,21], we followed the forensic standards
previously proposed by Cerezo et al. [22]. In agreement with the
literature [31], all mouse samples differed from the reference
sequence by homoplasmic transition 9461T.C and homoplasmic
transversion 7778G.T [23] (Figure 5A). Moreover, all of the
samples showed length heteroplasmy around the homopolymeric
tract ranging from position 5172 to position 5182 (Figure 5A). The
adenine homopolymeric tract located between positions 9821 and
9828 showed subtle length heteroplasmy in all astrocyte samples,
but a more pronounced length heteroplasmy in the cell lines
derived from the tumor samples (T653 and T731; Figure 5A).
Slippage of the Taq polymerase could explain these heteroplas-
mies given the length of both homopolymeric tracks, namely 11
and 10 adenines, respectively. Instabilities at homopolymeric
regions are normal in healthy individuals, as already demonstrated
in human studies [32] (Figure 5A). Since all of these variants were
Figure 2. Activated oncogenes: HRas
V12 promotes chromosomal instability. The primary astrocytes and the cell lines T653 and T731 were
treated with colcemid to induce metaphase arrest and then harvested for karyotype analysis. Between 30 and 40 metaphases from three
independent infections were counted in each case.
doi:10.1371/journal.pone.0023327.g002
Figure 3. Quantification of cytochrome c oxidase activity. Comparison of respiratory activity between primary astrocytes (cRb
loxP/loxP, cRb
2/2,
Rb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12) and tumor cell lines revealed greater mitochondrial activity in astrocytes Rb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12
than in the other cell groups, including cell lines T653 and T731.
doi:10.1371/journal.pone.0023327.g003
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they could play a role in the tumorigenic process. Finally, the cell
line T653 also differed from the reference sequence by the
heteroplasmies m.3573G/A and m.15907G/T (both positions at
,60:40), and cell line T731 by the heteroplasmy m.9348G/A
(,70:30). The minor variants of the latter indicate that the
heteroplasmies were non-synonymous, but this condition alone
does not support a pathogenic role (Figure 5A). For instance,
variant m.9348G.A defines a phylogenetic clade of mouse strains
including NOD, CBA, C3H/He, BALB(2), and A/J [31].
Analysis of human glioma mtDNA genomes
In addition, the mtDNA variation found in the entire genomes
of 11 human glioma samples (Table S3) was compared to
variations observed in human populations and reported in
GenBank and the literature (.7800 entire genomes) [33] Most
of this variation corresponded to expected polymorphisms
according to the haplogroup adscription. Figure 5B shows the
maximum parsimony tree of the 11 mtDNA genomes analyzed
here and also, for the sake of comparison, the mtDNA
phylogenetically related genomes observed in healthy individuals
previously reported in GenBank and/or the literature. All of the
samples belonged to typical European haplogroups, with the
exception of sample #02B13540, which belonged to the sub-
Saharan lineage L3x2b. The haplogroup distribution found in
patient mtDNAs fitted well with the one expected in a sample of
healthy individuals from the same geographical region [34]. Apart
from the basal mutations, all of the mtDNA profiles carried their
own set of private variants (tips of the phylogeny in Figure 5B) as
was expected given the fact that not all human genetic variations
have been recorded in the literature and databases. The gene
locations and functional characteristics of all the variants observed
in the human glioma mtDNAs are indicated in Table S4.
Discussion
Maintenance of mitochondrial genome integrity is of critical
importance to cell viability. In fact, the mechanisms that preserve
this integrity are conserved through evolution. Respiration-
deficient mutant yeast cells display elevated steady-state levels of
ROS that are associated with impairment in their cellular
antioxidant response, which compromises the viability of these
cells and shortens their lifespan [35]. Moreover, mtDNA is
susceptible to damage by an important number of anticancer
agents, thus mtDNA is a critical target for several compounds
currently used in the clinic, and a potential target for novel
chemotherapeutic agents [36]. Altogether, these highlight the
importance that the mitochondrial genome plays in cell survival
both in normal and tumor cells.
In the present study, we used a glioma model as a paradigm of
tumor initiation, progression and maintenance. As demonstrated
here, when a normal cell becomes tumoral, the cell starts to
respond to increased levels of ROS production with a rapid
antioxidant response. This response gives the cell the capability of
tolerating a toxic level of ROS; as a result, genomic instability
Figure 4. Mitochondrial changes in astrocytes. MitoTracker Red CMXRos fluorescence images of primary astrocytes 6 days after selection and
astrocyte lines T653 and T731. Oncogenic ras expression induced distribution of the mitochondria throughout the cell cytoplasm, whereas control
cells (Rb
loxP/loxP and cRb
2/2) showed a concentration of mitochondria around the nuclei of cells.
doi:10.1371/journal.pone.0023327.g004
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this transformation has taken place, the cell dramatically reduces
both ROS generation and its antioxidant response. Some authors
have described this so-called ‘‘mitochondrial silencing’’ as a
decrease in the mitochondrial activity found in cancer cells, as
reviewed in [37].
The mitochondrial genome was analyzed along the entire
evolution of the transformation process. A total of eight mouse
primary cell culture samples, two mouse cell line samples, and 11
human glioma samples were sequenced for the entire mtDNA
genome. In order to avoid false claims of mtDNA instability
[20,21], a strict laboratory protocol was followed according to
forensic standards [22]. In contrast to the high genomic instability
observed at the nDNA level, no instability was observed in the
mouse mtDNA complete genomes. On the other hand, the
variations observed in the human glioma mtDNA were compared
against the variation in the mtDNA genomes reported for healthy
individuals in public databases and the literature (.7800 complete
genomes). There is no a priori reason to believe that the variations
observed in the human glioma mtDNA play a role in
tumorigenesis because most of them are common and well-known
polymorphisms in the worldwide of mtDNA phylogeny. The few
new variants observed for the first time here fitted well with
expectations given the fact that not all human variations are
represented in databases. Our results are in good agreement with
the hypothesis supported by [20,21] from a theoretical basis,
indicating that most of the reported instabilities in tumor studies
are spurious, mainly due to the low quality DNA commonly used
in such studies that leads to errors of a different nature [20,21,38].
In a mouse model of gliomagenesis, we showed that multiple
and important alterations in the nDNA genome occur, as well as
alterations in the metabolism of the mitochondria. In contrast with
previous reports, the mtDNA molecule remains intact in
tumorigenesis in both mice gliomagenesis and in human gliomas.
Materials and Methods
Cell lines, cell culture and retroviral transduction
Astrocytes were generated from cRb
loxP/loxP neonatal mice at
day 3. The care and use of all experimental animals was in
accordance with institutional guidelines and approved by the
Ethics Committee of the University of Santiago de Compostela
and Xunta de Galicia (approval ID 15005AE/07/FUN01/FIS02/
JACP1). The cells were maintained in Dulbecco’s modified Eagle
medium (Sigma, St. Louis, MO, USA) with 10% fetal bovine
serum and 1% L-glutamine (GIBCO-Invitrogen, Barcelona,
Spain). In order to introduce an activated Ras allele and Rb loss
into the astrocytes, Phoenix-Eco packaging cells (a gift from G.P.
Nolan) were transfected with pBabe, pBabe-HRas
V12, PIG-puro
and PIG-CRE retroviral plasmids (a gift from P.P. Pandolfi). The
T653 and T731 cell lines were generated from tumors derived
from astrocytes modified by Rb
loxP/loxP/Ras
V12 and cRb
2/2/
Ras
V12, respectively (Table 1).
Determination of ROS production
Reactive oxygen species generation by astrocytes was detected
with the fluorescent probe DHE (Dihydtroethidium; Molecular
Probes, Carlsbad, CA, USA). Dihydtroethidium is a membrane-
permeable compound, which is oxidized to red fluorescent
ethidium (DNA binding membrane-impermeable compound) by
the action of radicals (O2
2). The astrocytes were incubated with
5 mM of DHE for 30 min at 37uC and protected from light.
Finally, intracellular ROS production was determined by the
increase in fluorescence observed by an Olympus IX70 fluores-
cence microscope under identical conditions in all experimental
groups.
Chromosome metaphase preparation
Metaphase spreads were prepared from exponentially growing
cells after treatment with colcemid. Cells were incubated in a
hypotonic buffer (0.05 M KCl, 0.0034 M trisodium citrate) for
20 min at 37uC and fixed in 75% methanol and 25% acetic acid.
The cells were then spotted onto microscope slides and stained
with 2% Wright in Gurr buffer (pH 7.0). Metaphase chromosomes
were scored using a Leika 2005 microscope under a 6100 oil
objective lens. T-FISH was performed on unstained metaphase
chromosomes using a Cy3-labeled peptide nucleic acid probe. For
T-FISH, both the DNA probe and the slides were heat denatured
(80uC for 5 min) and hybridized at 37uC for 2 h, in accordance
with the manufacturer’s specifications (Dako Cytomation,
Glostrup, Denmark). The slides were counterstained with DAPI
and the images were captured using a Leika 2005 microscope
equipped with the software program by Leika 4000. At least 50
metaphases were analyzed from three independent experiments.
Mitochondrial characterization
The number of mitochondria and their distribution were
determined using the MitoTracker Red CMXRos selective probe
(Molecular Probes, Barcelona, Spain). The cells were incubated in
a medium without FBS and containing 100 nM MitoTracker for
30 min at 37uC. The medium was then replaced with a complete
medium but without MitoTracker. Microscopic examination with
an Olympus IX70 fluorescence microscope was carried out.
Figure 5. Maximum parsimony trees of mouse and human mtDNA sequences. (A) Maximum parsimony tree of mtDNA entire genomes of
different mouse strains, primary cell cultures and cell lines. The phylogenetic skeleton of the different mouse strains was modified from Goios et al.
(2007). The violet squares at the bottom refer to the FVB/NJ strain samples analyzed in the present study, whereas the green squares indicate the cell
lines (sample ID is as in Table 1). Note that the C57BL/6J strain was used as the reference strain. Nucleotide changes along the branches are indicated
with respect to the reference strain (C57BL/6J). All mutations are transitions unless a suffix specifies a transversion (A, C, G, T), an insertion (+), a
deletion (d), a synonymous substitution (s), a mutational change in tRNA (-t), or amino acid replacements (indicated in round brackets). Recurrent
mutational events are underlined. (B) Maximum parsimony tree of human mtDNA gliomas. The blue rectangles indicate the entire mtDNA genomes
analyzed in the present study, whereas the violet rectangles are the genomes of healthy individuals phylogenetically to the gliomas analyzed in the
present study (GenBank accession numbers are indicated). The mutations are displayed along the branches (mutations of the control region in blue
script); the nomenclature is relative to the rCRS [24]. Haplogroups defined here for the first time are indicated in green rectangles. All mutations are
transitions unless a suffix specifies a transversion (A, C, G, T), a deletion (d), an insertion (+), a synonymous substitution (s), a mutational change in
tRNA (-t), a mutational change in rRNA (-r), or amino acid replacements (indicated in round brackets). Recurrent mutational events are underlined,
whereas @ indicates back mutations. Several mutational hotspot variants were not considered for the phylogenetic reconstruction and therefore
were eliminated from the tree; these included variants at the homopolymeric tracks around position 310, the microsatellite at m.523–524 (aka m.522–
523), the transversions m.16182A.C, m.16183A.C, m.16193+1C(C) and m.16519T.C, and length or point heteroplasmies. The codes of the samples
are indicated in blue rectangles at the terminal branches of the phylogeny. Note that sample DQ156208 [43] has an unusual number of reversions
that are probably due to documentation or sequencing errors [44].
doi:10.1371/journal.pone.0023327.g005
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Fresh purified mitochondrial samples from primary astrocytes and
cell lines in log-phase growth were used to monitor the mitochondrial
respiratory function (MITOISO2; Sigma, St. Louis, MO, USA).
Cytochrome c oxidase activity in membrane-bound mitochondrial
samples was determined by measuring the absorption changes of
cytochrome c at 550 nm. For this, we used the Cytochrome c
OxidaseAssay Kit CYTOCOX1from Sigma(St. Louis, MO, USA).
DNA samples
Primary mouse astrocytes cRb
loxP/loxP, cRb
2/2,R b
loxP/loxP/
Ras
V12 and cRb
2/2/Ras
V12, as well as the two cell lines T653 and
T731, were sequenced for the entire mtDNA genome.
The mtDNA genome of the strain C57BL/6J was used as the
reference sequence [39]. The revised Cambridge Reference
Sequence [40] was used as the reference for human samples.
DNA extraction
The primary mouse astrocytes and cell line samples were
solubilized with sodium dodecyl sulfate buffer and treated with
proteinase k (1 h at 55uC), with subsequent precipitation of the
DNA with ethanol. Human glioma samples were extracted
following standard phenol-chloroform protocols.
DNA sequencing of mouse and human mtDNA entire
genomes
The protocols carried out for primer design, Polymerase Chain
Reaction (PCR) and the sequencing reaction were previously described
[34], although slight modifications were made in the present study.The
mouse primers were designed in order to prevent them from annealing
at varying positions among the strains. Table S1 indicates the sequence
differences between the mtDNA genome of three different strains.
Most of the primers were previously reported [41,31]; some however,
were modified in order to improve PCR efficiency (Table S2). Primer 3
software (http://frodo.wi.mit.edu/cgi-bin/primer3) was used to design
the primers both PCR amplification and the sequencing reaction. All
of them had an annealing temperature around 60uCa n d5 8 uCf o rt h e
control regions in mouse and human DNA, respectively, and 55uCa n d
58uC for the coding regions in mouse and human DNA, respectively.
The National Centre for Biotechnology Information (NCBI; http://
www.ncbi.nlm.nih.gov) database was interrogated using BLAST in
order to test the primers against possible repetitive sequences and
sequence homologies in the nuclear genome. Each primer pair for
PCR amplification and sequencing was selected independently.
AutoDimer (http://www.cstl.nist.gov/biotech/strbase/AutoDimer
Homepage/AutoDimerProgramHomepage.htm) was used to test for
potential hairpin structures and primer-dimer problems. The melting
temperature (Tm) was double-checked using Primer 3 and Oligo
properties calculator (http://www.basic.northwestern.edu/biotools/
oligocalc.html) (Table S2). Primers for the amplification and
sequencing of human samples were previously described [42].
Polymerase chain reaction amplification was carried out in a
9700 Thermocycler (Applied Biosystems, Foster City, CA, USA)
using the PCR master mix QIAGEN Kit Multiplex PCR (Qiagen,
Dusseldorf, Germany). After a 95uC pre-incubation step for
15 min, PCR was performed in a total of 30–35 cycles using the
following conditions: 94uC denaturation for 30 s, annealing at
55uCt o6 0 uC (see details above) for 90 s, and extension at 72uC
for 90 s, followed by a 10 min of final extension at 72uC and 12uC
until removed from the thermocycler.
Before the sequencing reaction, the PCR products were purified
using MultiScreen PCR m 96 plates (Millipore, Billerica,
Massachusetts, USA).
The sequencing reaction was carried out in a total volume of
10 mL with 0.5 mL of the BigDyeH Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA),
2 mL of the 56 buffer of the BigDye kit, a primer at a
concentration of 0.3 mM, plus 3.5–4.5 mL of the PCR-purified
product. The reaction was performed in a 9700 Thermocycler
(Applied Biosystems, Foster City, CA, USA) following the
recommendations of the manufacturer: an activation step of
96uC for 3 min; then 25–30 cycles as follows: 96uC denaturation
for 30 s, 50uC annealing for 15 s, and 60uC extension for 4 min.
Unincorporated primers were eliminated by adding 1 mL of SAP
(GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire,
United Kingdom) for 80 min at 37uC followed by 15 min at 85uC
for enzyme inactivation. A final purification was carried out using
the Montage
TM SEQ96 Sequencing Reaction Cleanup Kit
(Millipore, Billerica, Massachusetts, USA), following the manu-
facturer’s instructions. Capillary electrophoresis was undertaken
on an ABI PRISM 3730xl Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). The resulting data were analyzed using
Sequencing Analysis and SeqScape Software (Applied Biosystems,
Foster City, CA, USA).
The six mouse and eleven human complete mtDNA genomes
analyzed in the present study are available in GenBank under
accession numbers HQ675026-HQ675031 and HQ675032-
HQ675042, respectively. Note that four of the sequences of the
primary astrocytes were replicated twice for the entire mtDNA
genome but only recorded by a single GenBank accession number.
The heteroplasmies and missing data (sample 04B11074) are
indicated in GenBank records under the same IUPAC code: ‘‘N’’
Supporting Information
Table S1 Nucleotide differences between the mtDNA genomes
of different mouse strains.
(DOC)
Table S2 Amplification and sequencing primers used for the
mouse samples.
(DOC)
Table S3 Variants observed on the 11 human glioma mtDNAs
sequenced in the present study for the entire genome, their gene
locations and functional characteristics.
(XLS)
Table S4 Gene locations and functional characteristics of all the
variants observed in the human glioma mtDNAs.
(XLS)
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